Vir Biotechnology Reminds Stockholders of 2021 Annual General Meeting Details
May 10, 2021 16:05 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, May 10, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) reminds stockholders that it will hold its 2021 Annual General Meeting of Stockholders on Thursday, May 20,...
GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19
May 07, 2021 05:53 ET
|
Vir Biotechnology, Inc.
– Rolling review will evaluate sotrovimab in adults and adolescents with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19 – – Review will...
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 06, 2021 16:05 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, May 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2021. ...
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2021 Financial Results on May 6, 2021
April 22, 2021 16:01 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, April 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter...
Brii Biosciences, Vir Biotechnology and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
April 21, 2021 08:00 ET
|
Vir Biotechnology, Inc.
DURHAM, N.C. and BEIJING and SAN FRANCISCO and CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Brii Biosciences (“Brii Bio”), Vir Biotechnology, Inc. (Nasdaq: VIR), and VBI Vaccines Inc....
GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
April 15, 2021 09:51 ET
|
Vir Biotechnology, Inc.
LONDON and SAN FRANCISCO, April 15, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Medicines Agency (EMA)...
Vir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host Cells
April 08, 2021 08:30 ET
|
Vir Biotechnology, Inc.
– Growing body of evidence suggests monoclonal antibodies that target a conserved epitope have the potential to be highly effective against SARS-CoV-2 and associated known mutations – – Newly...
Vir Biotechnology to Present at the 20th Annual Needham Virtual Healthcare Conference
April 06, 2021 16:01 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside...
Vir Biotechnology Announces New Preclinical Research Demonstrating VIR-7831 Maintains Neutralizing Activity Against the SARS-CoV-2 California Variant
April 05, 2021 08:00 ET
|
Vir Biotechnology, Inc.
– Data add to growing body of pre-clinical evidence demonstrating that VIR-7831 maintains activity against all known circulating variants of concern – – Plasma from vaccinated individuals and several...
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
March 29, 2021 08:30 ET
|
Vir Biotechnology, Inc.
INDIANAPOLIS and SAN FRANCISCO and LONDON, March 29, 2021 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today...